Objective: To assess the value of UroVysion FISH for screening urological malignancy and to explore its potential application in monitoring of recurrence of bladder cancer. Methods: Fresh urine specimens were collected from 368 cases with hematuria and/or history of urological cancer during follow-up. Diagnostic performance of UroVysion FISH for screening urological malignancy was evaluated in accordance with the results of pathology. Further analysis especially in patients with hematuria was conducted to determine the value of UroVysion FISH for detecting urological malignancy as well as for monitoring recurrence of bladder cancer. Results: ① The sensitivity of UroVysion FISH for detecting urological malignancy (bladder cancer, renal cancer, carcinoma of ureter, prostatic cancer) in patients with hematuria was superior to that without hematuria(P<0.005). ② Results of UroVysion Fish were closely related to tumor grade of urological malignancy. The sensitivity and specificity of UroVysion Fish for diagnosing high-stage tumor were higher than those of low-stage, especially in patients with hematuria. ③ A total of 45.51%(71/156) patients who eventually diagnosed as bladder cancer had cancer recurrence, and 57.75%(41/71) of them could be predicted according to the results of UroVysion Fish. ④ Results of FISH for bladder cancer follow-up in patients with hematuria showed higher sensitivity than in patients with history of urological malignancy. Conclusions: UroVysion FISH has high sensitivity and specificity for detecting urological malignancy, and the results are strongly relevant to tumor malignancy and invasion. UroVysion FISH is valuable for monitoring recurrence of bladder cancer, especially in patients with hematuria.
XU Ling, WANG Genfa, ZHANG Liang
. Diagnostic value of UroVysion FISH for detecting urological malignancy and its use in monitoring recurrence of bladder cancer[J]. Journal of Diagnostics Concepts & Practice, 2018
, 17(02)
: 159
-164
.
DOI: 10.16150/j.1671-2870.2018.02.008
[1] Griffiths TR, Action on Bladder Cancer. Current perspectives in bladder cancer management[J]. Int J Clin Pract,2013,67(5):435-448.
[2] Crawford JM.The origins of bladder cancer[J]. Lab Invest,2008,88(7):686-693.
[3] Grossman HB, Gomella L, Fradet Y, et al.A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer[J]. J Urol,2007,178(1):62-67.
[4] Sullivan PS, Nooraie F, Sanchez H, et al.Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study[J]. Cancer,2009,117(3):167-173.
[5] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2016[J]. CA Cancer J Clin,2016,66(1):7-30.
[6] Fadl-Elmula I, Gorunova L, Mandahl N, et al.Cytogene-tic analysis of upper urinary tract transitional cell carcinomas[J]. Cancer Genet Cytogenet,1999 ,115(2):123-127.
[7] Caraway NP, Khanna A, Fernandez RL, et al.Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study[J]. Cancer Cytopathol,2010,118(5):259-268.
[8] Hajdinjak T.UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing[J]. Urol Oncol,2008, 26(6):646-651.
[9] Dimashkieh H, Wolff DJ, Smith TM, et al.Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation[J]. Cancer Cytopathol,2013,121(10):591-597.
[10] Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al.Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus[J]. Urol Int,2015,94(1):1-24.
[11] Karaoglu I, van der Heijden AG, Witjes JA. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer[J]. World J Urol, 2013,32(3):651-659.
[12] Black PC, Brown GA, Dinney CP.Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer[J]. J Clin Oncol,2006,24(35): 5528-5535.
[13] Gudjónsson S, Isfoss BL, Hansson K, et al.The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer[J]. Eur Urol,2008,54(2):402-408.
[14] Ather MH, Nazim SM.New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer[J]. Korean J Urol,2015,56(8):553-564.
